The new paradigm of systemic therapies for metastatic melanoma.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28711086.
- Also identified by DOI 10.1016/j.jaad.2017.04.1126.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
New treatments for metastatic melanoma work through distinct mechanisms: enhancing the immune response and blocking cellular proliferation. Agents that enhance the immune response include ipilimumab, pembrolizumb, and nivolumab; agents that block cellular proliferation include vemurafenib, dabrafenib, trametinib, cobimetinib, binimetinib, and selumetinib. The translational impact of laboratory discoveries has revolutionized management of metastatic melanoma and enhanced the prognosis of affected patients.
Medical subject headings
- Antineoplastic Agents
- Immunologic Factors
- Melanoma
- Protein Kinase Inhibitors
- Skin Neoplasms